Gastrointestinal Stromal Tumors: Review on Morphology, Molecular Pathology, Prognosis, and Differential Diagnosis
Top Cited Papers
Open Access
- 1 October 2006
- journal article
- review article
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 130 (10) , 1466-1478
- https://doi.org/10.5858/2006-130-1466-gstrom
Abstract
Context.—Gastrointestinal stromal tumors (GISTs) are specific, generally Kit (CD117)-positive, mesenchymal tumors of the gastrointestinal tract encompassing a majority of tumors previously considered gastrointestinal smooth muscle tumors. They are believed to originate from interstitial cells of Cajal or related stem cells. Objective.—To review current clinicopathologically relevant information on GIST. Data Sources.—Literature in Medline and authors' own experience. Conclusions.—GISTs usually occur in older adults (median age 55–60 years) and rarely in children in the second decade (502-Tyr503 duplication is specific for intestinal GISTs. Mutations in PDGFRA have been identified in juxtamembrane (exon 12) and tyrosine kinase domains (exons 14 and 18), nearly exclusively in gastric GISTs, mostly in epithelioid variants. Some Kit and PDGFRA mutations have a prognostic value. Kit/PDGFRA tyrosine kinase inhibitor imatinib has been successfully used in the treatment of metastatic GISTs for more than 5 years. However, primary and acquired secondary resistance linked to certain types of Kit and PDGFRA mutations is limiting long-term success necessitating the use of alternative treatments.Keywords
This publication has 93 references indexed in Scilit:
- Factors Associated With Disease Progression in Patients With Gastrointestinal Stromal Tumors in the Pre-Imatinib EraAmerican Journal of Clinical Pathology, 2005
- PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to ImatinibJournal of Clinical Oncology, 2005
- Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate eraCancer, 2005
- Novelc-KIT germline mutation in a family with gastrointestinal stromal tumors and cutaneous hyperpigmentationAmerican Journal of Medical Genetics Part A, 2004
- Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor siteLaboratory Investigation, 2004
- Gastrointestinal Stromal Tumors with Internal Tandem Duplications in 3′ End of KIT Juxtamembrane Domain Occur Predominantly in Stomach and Generally Seem to Have a Favorable CourseLaboratory Investigation, 2003
- Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinaseProceedings of the National Academy of Sciences, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal TumorsThe American Journal of Pathology, 2000
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998